Bruce Stroever - 04 Jun 2025 Form 4 Insider Report for Bone Biologics Corp (BBLG)

Role
Director
Signature
/s/ Bruce Stroever
Issuer symbol
BBLG
Transactions as of
04 Jun 2025
Net transactions value
$0
Form type
4
Filing time
06 Jun 2025, 17:01:18 UTC
Previous filing
19 Sep 2024

Quoteable Key Fact

"Bruce Stroever filed Form 4 for Bone Biologics Corp (BBLG) on 06 Jun 2025."

Quick Takeaways

  • This page summarizes Bruce Stroever's Form 4 filing for Bone Biologics Corp (BBLG).
  • 1 reported transaction and 6 derivative rows are listed below.
  • Filing timestamp: 06 Jun 2025, 17:01.

What Changed

  • Previous filing in this sequence was filed on 19 Sep 2024.
  • Current net transaction value: $0.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Source Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Stroever Bruce Director C/O BONE BIOLOGICS CORP,, 2 BURLINGTON WOODS DR.SUITE 100, BURLINGTON, /s/ Bruce Stroever 06 Jun 2025 0001657728

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBLG Non-Employee Stock Option Award $0 +62,894 $0.000000 62,894 04 Jun 2025 Common Stock 62,894 $0.8800 Direct F1
holding BBLG Non-Employee Stock Option 30,713 04 Jun 2025 Common Stock 30,713 $1.73 Direct F2
holding BBLG Non-Employee Stock Option 10,721 04 Jun 2025 Common Stock 10,721 $5.12 Direct F3
holding BBLG Non-Employee Stock Option 154 04 Jun 2025 Common Stock 154 $387.28 Direct F3
holding BBLG Non-Employee Stock Option 37 04 Jun 2025 Common Stock 37 $844.80 Direct F3
holding BBLG Non-Employee Stock Option 13 04 Jun 2025 Common Stock 13 $1260.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests in four equal quarterly installments.
F2 This option was granted on 9/17/2024 and vests in four equal quarterly installments.
F3 This option is fully exercisable as of the date of this report.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .